Clinical Trial Update: Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures [Phase 4]

View source ↗

Summary

Phase 4 dose-optimization study of ezogabine/retigabine IR as adjunctive treatment in partial-onset seizures was terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial-onset Seizures
• Seizures

Drugs mentioned

• Ezogabine/Retigabine (ezogabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Seizures | Phase 4 | Status: TERMINATED | Results posted: 2014-03-26